Andy Roddick defends Serena Williams' GLP-1 weight loss amid comeback talk

Former tennis star Andy Roddick has voiced support for Serena Williams' use of GLP-1 medication in her weight-loss efforts, suggesting it could aid a potential return to the court. Williams has shared how the treatment improved her health, while speculation grows following her inclusion in the anti-doping pool and practice sessions with younger players. Roddick emphasized the benefits for injury prevention during training.

In a recent episode of the Served podcast, Andy Roddick addressed criticism of Serena Williams' use of GLP-1 medication for weight loss. He stated that if he were attempting a comeback, he would prioritize rapid weight reduction to facilitate safer training. "I can tell you something that I think I know for a fact, right? I’m not Serena. I can’t play anymore. I stink. And if I decided that I wanted to come back, guess what I would be doing immediately? Immediately, I’d be dropping 20 pounds as fast as I can," Roddick said.

Roddick argued that starting lighter reduces injury risks during preparation, which is a major hurdle for returning athletes. "I would be taking those drugs because you know what becomes easier when you are 20 pounds lighter? Actually, getting back to the training that you need without getting injured to get back on tour," he explained. He added, "What it does is shortens the timeline for training and mitigates a lot of the risk in because the thing with getting back is like you get injured training, injured training, injured training, you can’t get back. Right."

Williams first discussed her use of the medication in an August 2025 interview with People Magazine and reinforced it in a Super Bowl XL advertisement in 2026. In a January 2026 interview with Today.com, she highlighted health improvements: "My blood sugar is better. I was able to lower my cholesterol by 30%. Some of these numbers [previous high cholesterol levels] are from when I was literally winning Grand Slams. It wasn’t, like, just playing tennis. I was dominating. I was at risk for heart disease, and I didn’t even know. … That’s scary."

Comeback rumors intensified after Williams' name appeared in the tennis anti-doping testing pool, a step often required for returning players. On the Today show in January 2026, she responded ambiguously: "I’m just having fun and enjoying my life right now," adding, "I don’t know, I’m just going to see what happens."

American player Alycia Parks recently practiced with Williams and commented on her fitness. "I actually practiced with her last Monday. And I messaged her yesterday. She’s definitely a good mentor to me, and she’s helped me a lot, especially in my practices," Parks told Tennis Majors. She added, "She is in great shape. So I think she would kill it on tour."

Support for Williams continues to build in the tennis community as discussions of a potential return, possibly emulating sister Venus, persist.

Verwandte Artikel

Serena Williams, fit and transformed, poses athletically with tennis racket against Super Bowl ad for Zepbound weight loss drug.
Bild generiert von KI

Serena Williams in Super-Bowl-Werbung für Abnehmmedikament

Von KI berichtet Bild generiert von KI

Serena Williams wird in einer Super-Bowl-Werbung für das Telehealth-Unternehmen Ro und sein GLP-1-Abnehmmedikament Zepbound auftreten. Die 44-jährige Tennislegende spricht über ihre Körpertransformation, bei der sie seit Behandlungsbeginn bis zu 15,4 kg verloren hat. Die Werbung kommt inmitten anhaltender Spekulationen über ein mögliches Comeback im Profi-Tennis.

Die International Tennis Integrity Agency hat Serena Williams offiziell als aktive Spielerin wieder aufgenommen und sie am 22. Februar 2026 von der Liste der Rücktrittspielerinnen gestrichen. Dieser Schritt folgt ihrer Rückkehr in den Anti-Doping-Testpool im Vorjahr, was sie für Turniere qualifiziert. Ihr ehemaliger Coach Rick Macci äußerte Gewissheit über ein Comeback und berief sich auf ihr intensives Training.

Von KI berichtet

Country star Jelly Roll has dropped nearly 300 pounds over two years without using popular GLP-1 medications like Ozempic. The 41-year-old singer opened up in Men's Health about tackling his food addiction through therapy instead. From low testosterone woes to reignited romance, he's spilling all the transformative tea.

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

Von KI berichtet

Coco Gauffs Viertelfinal-Aus beim Australian Open 2026 wurde kontrovers, als Videos von ihr, die ihre Rakete zertrümmert, viral gingen. Tennis-Legende Serena Williams bot Ermutigung, während mehrere Spieler Bedenken hinsichtlich der Privatsphäre in Spielerbereichen äußerten. Der Vorfall beleuchtete die emotionalen Belastungen, denen Athleten ausgesetzt sind.

Die Top-Tennisspieler Carlos Alcaraz, Jannik Sinner und Aryna Sabalenka wurden angewiesen, ihre Whoop-Fitness-Tracker während der Australian Open 2026 abzulegen. Die Geräte, die für ATP- und WTA-Touren zugelassen sind, bleiben bei Grand-Slam-Turnieren verboten, inmitten anhaltender Debatten über Spielerwohl und Datenregeln. Die Turnierveranstalter besprechen eine mögliche künftige Zulassung.

Von KI berichtet

Retired tennis player Eugenie Bouchard has discussed the upheaval in her life following her 2014 Wimbledon final appearance, which brought sudden fame and high expectations. She described a rebellious phase that included a drastic hairstyle change, leading to the loss of a sponsorship deal. Now focused on pickleball, Bouchard emphasizes the complexity beyond her public image.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen